Advertisement

Schnitzler Syndrome

  • Paolo SfrisoEmail author
  • Paola Galozzi
Chapter

Abstract

The Schnitzler syndrome is a chronic non-pruritic urticaria within a monoclonal IgM gammopathy, associated with recurrent fever, arthralgia, weight loss and lymphadenopathy. Leucocytosis and altered inflammatory markers could be observed. Thus, the disease is now considered a late-onset acquired autoinflammatory syndrome. Diagnosis relies on a combination of clinical, biological and radiological findings as well as on exclusion of other causes. Currently, there is no approved treatment for the Schnitzler syndrome. Interleukin-1 blocking agents seem to be the most effective therapies, even though only on the inflammation-linked symptoms, not on the monoclonal component.

Keywords

Schnitzler syndrome Urticarial rash Monoclonal gammopathy Autoinflammatory disease Interleukin-1 IL-1 inhibitors 

References

  1. 1.
    Schnitzler L. Lésions urticariennes chroniques permanentes (érythème pétaloïde?). Journées Dermatologiques d’Angers. 1972; Cas Clinique. N°46b.Google Scholar
  2. 2.
    Schnitzler L, Schubert B, Verret JL, Simon L, Alquier P. Cutaneous manifestations in disseminated intravascular coagulation syndrome. Ann Dermatol Syphiligr. 1976;103:124–34.Google Scholar
  3. 3.
    Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31:45–52.CrossRefGoogle Scholar
  4. 4.
    Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al. Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68:562–8.CrossRefGoogle Scholar
  5. 5.
    de Koning HD. Schnitzler’s syndrome: lessons from 281 cases. Clin Transl Allergy. 2014;4:41.CrossRefGoogle Scholar
  6. 6.
    de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler Syndrome Study Group: Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37(3):137–48.CrossRefGoogle Scholar
  7. 7.
    Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis. 2010;5:38.CrossRefGoogle Scholar
  8. 8.
    Pizzirani C, Falzoni S, Govoni M, La Corte R, Donadei S, Di Virgilio F, et al. Dysfunctional inflammasome in Schnitzler’s syndrome. Rheumatology (Oxford). 2009;48(10):1304–8.CrossRefGoogle Scholar
  9. 9.
    Noster R, de Koning HD, Maier E, Prelog M, Lainka E, Zielinski CE. Dysregulation of proinflammatory versus anti-inflammatory human TH17 cell functionalities in the autoinflammatory Schnitzler syndrome. J Allergy Clin Immunol. 2016;138:1161–9.CrossRefGoogle Scholar
  10. 10.
    de Koning HD, van Gijn ME, Stoffels M, Jongekrijg J, Zeeuwen PL, Elferink MG, et al. Myeloid lineage–restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol. 2015;135:561–4.CrossRefGoogle Scholar
  11. 11.
    Varella TC, Nishimura MY, Machado MC, de Moraes-Vasconcelos D, Rivitti EA. Schnitzler’s syndrome without monoclonal gammopathy. Acta Derm Venereol. 2005;85:272–3.PubMedGoogle Scholar
  12. 12.
    Urbanski M, Holfeld K, Milne A, Abbas M. Schnitzler syndrome without a monoclonal gammopathy: a case report. J Cutan Med Surg. 2016;20:575–8.CrossRefGoogle Scholar
  13. 13.
    Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 2001;80(1):37–44.CrossRefGoogle Scholar
  14. 14.
    Olsen E, Forre O, Lea T, Langeland T. Unique antigenic determinants (idiotypes) used as markers in a patient with macroglobulinemia urticaria: similar idiotypes demonstrated in the skin and on peripheral blood lymphocytes. Acta Med Scan. 1980;207:379–84.CrossRefGoogle Scholar
  15. 15.
    Niederhauser BD, Dingli D, Kyle RA, Ringler MD. Imaging findings in 22 cases of Schnitzler syndrome: characteristic para-articular osteosclerosis, and the “hot knees” sign differential diagnosis. Skelet Radiol. 2014;43:905–15.CrossRefGoogle Scholar
  16. 16.
    Ferrando FJ, Pujol J, Hortells JR, et al. Schnitzler’s syndrome: report of a case with bone osteolysis. J Investig Allergol Clin inmunol. 1994;4:203–5.Google Scholar
  17. 17.
    Willekens I, Walgraeve N, Goethals L, De Geeter F. Correlative bone imaging in a case of Schnitzler’s syndrome and brief review of the literature. Hell J Nucl Med. 2015;18:71–3.PubMedGoogle Scholar
  18. 18.
    Carlesimo M, Abruzzese C, Narcisi A, La Verde G, De Marco G, Verga E, et al. Chronic vasculitis urticaria associated to a monoclonal gammopathy of IgM and IgA type, a Schnitzler syndrome? Eur J Dermatol. 2010;20:838–9.PubMedGoogle Scholar
  19. 19.
    Gusdorf L, Asli B, Barbarot S, Neel A, Masseau A, Puechal X, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy. 2017;72:177–82.CrossRefGoogle Scholar
  20. 20.
    Berdy SS, Bloch KJ. Schnitzler’s syndrome: a broader clinical spectrum. J Allergy Clin Immunol. 1991;87:849–54.CrossRefGoogle Scholar
  21. 21.
    van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984–96.CrossRefGoogle Scholar
  22. 22.
    Machet L, Vaillant L, Machet MC, Reisenleiter M, Goupille P, Lorette G. Schnitzler ’ s syndrome (urticaria and macroglobulinemia): evolution to Waldenström’s disease is not uncommon. Acta Derm Venereol (Stockh). 1996;76:413.Google Scholar
  23. 23.
    Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158(1):182–4.PubMedGoogle Scholar
  24. 24.
    Basile C, Rossi L, Casucci F, Teutonico A, Libutti P, Lisi P, et al. Kidney involvement in the Schnitzler syndrome, a rare disease. Clin Kidney J. 2017;10(6):723–7.CrossRefGoogle Scholar
  25. 25.
    Bursztejn AC, Imperiale A, Lipsker D. Aortitis: a new feature of Schnitzler syndrome. JAAD Case Rep. 2017;3:454–6.CrossRefGoogle Scholar
  26. 26.
    Lipsker D, Lenormand C. Management of Schnitzler’s syndrome. Expert Opin Orphan Drugs. 2014;2:947–55.CrossRefGoogle Scholar
  27. 27.
    Kastritis E, Katoulis A, Terpos E, Panayiotides I, Gavriatopoulopu M, Dimopopoulos MA. Schnitzler’s syndrome: increased levels of bone formation and angiogenesis factors are reduced after successful pefloxacin treatment. Clin Lymphoma Myeloma. 2008;8:359–62.CrossRefGoogle Scholar
  28. 28.
    Martinez-Taboada VM, Fontalba A, Blanco R, Fernández-Luna JL. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 2005;52(7):2226–7.CrossRefGoogle Scholar
  29. 29.
    Cascavilla N, Bisceglia M, D’Arena G. Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int J Immunopathol Pharmacol. 2010;23(2):633–6.CrossRefGoogle Scholar
  30. 30.
    Neel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev. 2014;13:1035–41.CrossRefGoogle Scholar
  31. 31.
    Perrin F, Neel A, Graveleau J, Ruellan AL, Masseau A, Hamidou M. Two cases of anakinra-induced neutropenia during auto-inflammatory diseases: drug reintroduction can be successful. Presse Med. 2014;43:319–21.CrossRefGoogle Scholar
  32. 32.
    Pesek R, Fox R. Successful treatment of Schnitzler syndrome with canakinumab. Cutis. 2014;94:E11–2.PubMedGoogle Scholar
  33. 33.
    De Koning HD, Schalkwijk J, van der Ven-Jongekrijg J, Stoffels M, van der Meer JWM, Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann Rheum Dis. 2013;72:1634–8.CrossRefGoogle Scholar
  34. 34.
    Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. Semin Arthritis Rheum. 2013;42:413–6.CrossRefGoogle Scholar
  35. 35.
    Krause K, Tsianakas A, Wagner N, Fischer J, Weller K, Metz M, et al. Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. J Allergy Clin Immunol. 2017;139:1311–20.CrossRefGoogle Scholar
  36. 36.
    Krause K, Weller K, Stefaniak R, Wittkowski H, Altrichter S, Siebenhaar F, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943–50.CrossRefGoogle Scholar
  37. 37.
    Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol. 2012;129:848–50.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Unit of Rheumatology, Department of Medicine – DIMEDUniversity of PadovaPadovaItaly

Personalised recommendations